Drug delivery and development company CURE Pharmaceutical Holding Corp (OTC: CURR) has entered into a partnership with Canadian cannabis giant Canopy Growth Corp (NYSE: CGC) to develop a CBD product together.
What To Know
The companies will be working on a low-dose CBD oral thin film that will use CURE Pharmaceutical's patented CUREfilm technology. Canopy Growth will license the technology for global distribution.
CUREfilm will offer Canopy Growth a dosage that is "ideal for administering cannabinoids," CURE said in a statement.
Need more cannabis news? Check out all of our coverage here.
This latest development builds on the licensing deal that CURE and Canopy entered into back in September. Under the terms of the agreement, Canopy obtained exclusive license to CUREfilm for use with cannabis extracts and biosynthetic cannabinoids in global markets.
Why It's Important
Through this partnership, CURE Pharmaceutical will be able to leverage its patented technology and expand it on a global scale. CURE is registered with the U.S. Drug Enforcement Agency to develop and manufacture cannabis-derived and synthetic cannabinoid products that use CUREfilm for pharmaceutical applications. The company has a production facility in Oxnard, California.
Canopy Growth will have a product that provides an easier and more efficient way to deliver cannabinoids. CUREfilm provides increased bioavailability and more precise dosing.
CURE Pharmaceutical Expands DEA License To Manufacture Cannabinoid Molecules
Canopy Growth Announces Colombian Manufacturing Agreement For Oil-Based Products
See more from Benzinga
- The Week Ahead In Cannabis: Canopy Earnings, CannaCon In Detroit And More
- Canopy Growth Acquires London-Based Skincare Company This Works For M
- Canopy Growth, PharmHouse Enter Into Supply Agreement
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.